Chapter/Section Purchase

1 Study Coverage
1.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022) & (US$ Million) Introduction
1.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Outlook 2017 VS 2022 VS 2028
1.2.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size for the Year 2017-2028
1.2.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size for the Year 2017-2028
1.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Gastrointestinal Stromal Tumors (GSTs) Treatment in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Dynamics
1.4.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Industry Trends
1.4.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers
1.4.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Challenges
1.4.4 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Gastrointestinal Stromal Tumors (GSTs) Treatment by Type
2.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Segment by Type
2.1.1 Surgery
2.1.2 Targeted Therapy
2.1.3 Radiation Therapy
2.1.4 ChemOthersapy
2.1.5 Others
2.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2017, 2022 & 2028)
2.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2017-2028)
2.4 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2017, 2022 & 2028)
2.5 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type (2017-2028)
3 Gastrointestinal Stromal Tumors (GSTs) Treatment by Application
3.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Surgical Centers
3.1.4 Others
3.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2017, 2022 & 2028)
3.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2017-2028)
3.4 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2017, 2022 & 2028)
3.5 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application (2017-2028)
4 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Competitor Landscape by Company
4.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Company
4.1.1 Top Global Gastrointestinal Stromal Tumors (GSTs) Treatment Companies Ranked by Revenue (2021)
4.1.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Player (2017-2022)
4.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Concentration Ratio (CR)
4.2.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Gastrointestinal Stromal Tumors (GSTs) Treatment in 2021
4.2.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Headquarters, Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022) & (US$ Million) Type
4.3.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Headquarters and Area Served
4.3.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Companies Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Gastrointestinal Stromal Tumors (GSTs) Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Company
4.5.1 Top Gastrointestinal Stromal Tumors (GSTs) Treatment Players in United States, Ranked by Revenue (2021)
4.5.2 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region
5.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region (2017-2028)
5.2.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region: 2017-2022
5.2.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size YoY Growth 2017-2028
6.1.2 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size YoY Growth 2017-2028
6.3.2 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size YoY Growth 2017-2028
6.4.2 Latin America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Details
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.1.4 Pfizer Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.1.5 Pfizer Recent Development
7.2 Bayer
7.2.1 Bayer Company Details
7.2.2 Bayer Business Overview
7.2.3 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.2.4 Bayer Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.2.5 Bayer Recent Development
7.3 Novartis
7.3.1 Novartis Company Details
7.3.2 Novartis Business Overview
7.3.3 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.3.4 Novartis Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.3.5 Novartis Recent Development
7.4 Immunicum
7.4.1 Immunicum Company Details
7.4.2 Immunicum Business Overview
7.4.3 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.4.4 Immunicum Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.4.5 Immunicum Recent Development
7.5 Roche
7.5.1 Roche Company Details
7.5.2 Roche Business Overview
7.5.3 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.5.4 Roche Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.5.5 Roche Recent Development
7.6 AB Science
7.6.1 AB Science Company Details
7.6.2 AB Science Business Overview
7.6.3 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.6.4 AB Science Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.6.5 AB Science Recent Development
7.7 Arog Pharmaceuticals
7.7.1 Arog Pharmaceuticals Company Details
7.7.2 Arog Pharmaceuticals Business Overview
7.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.7.4 Arog Pharmaceuticals Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.7.5 Arog Pharmaceuticals Recent Development
7.8 Boston Biomedical
7.8.1 Boston Biomedical Company Details
7.8.2 Boston Biomedical Business Overview
7.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.8.4 Boston Biomedical Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.8.5 Boston Biomedical Recent Development
7.9 Sun Pharmaceutical
7.9.1 Sun Pharmaceutical Company Details
7.9.2 Sun Pharmaceutical Business Overview
7.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.9.4 Sun Pharmaceutical Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.9.5 Sun Pharmaceutical Recent Development
7.10 Natco Pharma
7.10.1 Natco Pharma Company Details
7.10.2 Natco Pharma Business Overview
7.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Introduction
7.10.4 Natco Pharma Revenue in Gastrointestinal Stromal Tumors (GSTs) Treatment Business (2017-2022)
7.10.5 Natco Pharma Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer